| |FEBRUARY 20259JUPITER NEUROSCIENCES AND CATALENT PARTNER TO PRODUCE JOTROL SOFTGEL CAPSULESAKUMS COMBINES TWO POTENT DIABETES MEDICINES FOR ENHANCED TREATMENT EFFICACYJupiter Neurosciences Inc., a pharmaceutical company in the clinical stage, is developing JOTROL, a patented platform based on resveratrol, and has reached an agreement with Catalent Pharma Solutions LLC to produce JOTROL softgel capsules to assist Jupiter's forthcoming Phase 2a clinical trial for Parkinson's disease.As per the agreement, Catalent will produce clinical batches of JOTROL, Jupiter's exclusive resveratrol-based therapy, utilizing an enhanced softgel formulation. The study on Parkinson's will comprise both active and placebo batches in its production."Securing an experienced CDMO leader like Catalent is a critical step as we advance JOTROL into clinical development for Parkinson's disease," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "Catalent's industry-leading expertise in pharmaceutical manufacturing and its ability to scale production efficiently according to a tight timeline will help us maintain momentum in our development program and support our goal of delivering innovative therapies to patients."The forthcoming Phase 2a study will assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of JOTROL in patients with Parkinson's disease over a duration of three months.Jupiter Neurosciences Inc is a pharmaceutical firm focused on clinical stage research and development based in the USA. The company has created a distinctive resveratrol platform product mainly focused on addressing neuro-inflammation treatment. Its platform product, JOTROL, provides possible therapeutic advantages for various central nervous system conditions, including Alzheimer's disease, ataxias, and metabolic disorders like Lysosomal Storage Disorders and mitochondrial diseases. POAkums Drugs and Pharmaceuticals, a leader in contract development and manufacturing, has launched Dapagliflozin + Pioglitazone tablets; an advanced combination therapy designed to tackle the growing challenge of diabetes management. While conventional treatments often fall short in maintaining stable blood sugar levels, this dual-action formulation offers a more potent solution for individuals struggling with existing metformin-based regimens. Approved by the Drugs Controller General of India (DCGI), it goes beyond glycemic control, overcoming broader obstacles associated with diabetes care.Compared to monotherapy, this dual approach ensures more comprehensive blood sugar regulation by addressing multiple pathways simultaneously. While single-drug regimens may provide partial benefits, the combined action of Dapagliflozin and Pioglitazone offers superior control, reducing fluctuations in glucose levels more effectively. Commenting on the launch, Mr. Sandeep Jain, Managing Director of Akums Drugs and Pharmaceuticals, stated, "The rise in diabetes cases in our country calls for novel and accessible solutions. By introducing Dapagliflozin + Pioglitazone tablets, we aim to equip healthcare providers with an advanced treatment option that caters to the diverse needs faced by patients. Our goal is to deliver therapies that make a real difference in people's lives."Type 2 diabetes disrupts the way the body uses glucose for energy, impairing insulin function and leading to elevated blood sugar levels if untreated. Over time, it can cause serious health issues, particularly affecting the nerves and blood vessels.As diabetes continues to burden healthcare systems and individuals alike, Akums is setting a benchmark in pharmaceutical innovation, providing the medical community with solutions that tackle both the complexities and consequences of this growing epidemic. PO
< Page 8 | Page 10 >